menu ☰
menu ˟

Empagliflozin reduces liver fat in patients with type 2 diabetes, NAFLD

20 Mar 2018
Ambrish MithalCHICAGO — Empagliflozin, an oral SGLT2 inhibitor, may provide substantial benefit to patients with type 2 diabetes and nonalcoholic fatty liver disease by aiding in the reduction of liver fat, according to findings from the E-LIFT tri...

Click here to view the full article which appeared in Hepatology

IPH Logo